Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vaxil Bio Ltd (VXL.VN)

Vaxil Bio Ltd (VXL.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vaxil Bio Ltd C/O Kira Lynn, Bennet Jones LLP 3400 One First Canadian Place Toronto ON M5X 1A4 CAN

P: 647-558-5564 F: 647-351-6200

Description:

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin, a COVID19 and a tuberculosis vaccine/treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Key Statistics

Overview:

Market Capitalization, $K 8,881
Shares Outstanding, K 136,629
Annual Sales, $ 0 K
Annual Net Income, $ -1,358 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -209 K
60-Month Beta -3.71

Growth:

1-Year Return -42.86%
3-Year Return -18.75%
5-Year Return -51.85%
5-Year Revenue Growth 0.00%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.00
EPS Growth vs. Prev Year 47.10%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-2 on 03/10/16

VXL.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -104.59%
Return-on-Assets % -70.19%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity N/A
Price/Sales N/A
Price/Book 4.08
Book Value/Share 0.02
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar